search
Back to results

Systematic Sampling of Lymph Nodes vs. Lymphadenectomy According to Intraoperative Frozen Pathology for Pulmonary Invasive Adenocarcinoma With Ground-glass Opacity

Primary Purpose

Lymph Node Excision

Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
systematic sampling of the lymph-node
lymphadenectomy
Sponsored by
Shanghai Pulmonary Hospital, Shanghai, China
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Lymph Node Excision

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. A peripheral nodular lesion;
  2. The maximum diameters of whole GGO lesions and solid components on lung windows were no more than 3 cm (T1 stage);
  3. VATS lobectomy
  4. 25%≦Consolidation/Tumor ratio ≦50%
  5. ECOG performance status 0-2;
  6. Without distant metastasis;
  7. Intraoperative frozen pathology confirmed invasive or minimally invasive adenocarcinoma.
  8. No operation contraindication
  9. Cardiovascular: Cardiac function normal
  10. Renal: Creatinine clearance greater than 60 ml/min
  11. The expected survival after surgery ≥ 6 months
  12. Must be able to sign written informed consent form

Exclusion Criteria:

  1. Age less than 18 years old
  2. Known hereditary bleeding disorder with history of post-operative hemorrhage
  3. Patients maintained on chronic anticoagulation (eg Coumadin therapy)
  4. Known hematogenous disorder
  5. Known primary or secondary malignancy
  6. Pregnant or breast-feeding women;
  7. Clinically significant heart disease;
  8. Patients who are unwilling or unable to comply with study procedures;
  9. Receiving immunosuppressive therapy;
  10. HIV/AIDS.
  11. Multiple lesions in lung

Sites / Locations

  • Shanghai Pulmonary HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Lymphadenectomy

systematic sampling of the lymph nodes

Arm Description

systematically Lymphadenectomy of the lymph-node stations ATS 2, 4, 7, 8, 9,10,11 on the right side and ATS 5, 6, 7, 8, 9,10,11 on the left side

systematic sampling of the lymph-node stations ATS 2, 4, 7, 8, 9,10,11 on the right side and ATS 5, 6, 7, 8, 9,10,11 on the left side

Outcomes

Primary Outcome Measures

recurrence-free survival
recurrence-free survival status of patients after surgery

Secondary Outcome Measures

Overall Survival
survival status of patients after surgery
Morbidity rate
the rates of complications related to treatment during perioperative period
Mortality rate
the rates of death related to treatment during perioperative period

Full Information

First Posted
October 23, 2017
Last Updated
December 15, 2017
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Collaborators
Changhai Hospital, Shanghai 10th People's Hospital, Ruijin Hospital, RenJi Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03322826
Brief Title
Systematic Sampling of Lymph Nodes vs. Lymphadenectomy According to Intraoperative Frozen Pathology for Pulmonary Invasive Adenocarcinoma With Ground-glass Opacity
Official Title
A Prospective and Multi-center RCT Study of Lymphadenectomy Based on Intraoperative Frozen Pathology for Pulmonary Invasive Adenocarcinoma Presenting With Ground Glass Opacity
Study Type
Interventional

2. Study Status

Record Verification Date
December 2017
Overall Recruitment Status
Recruiting
Study Start Date
December 8, 2017 (Actual)
Primary Completion Date
October 28, 2021 (Anticipated)
Study Completion Date
October 28, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Collaborators
Changhai Hospital, Shanghai 10th People's Hospital, Ruijin Hospital, RenJi Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to evaluate the impact of systematic sampling of lymph nodes vs. lymphadenectomy on outcome according to intraoperative frozen pathology for pulmonary invasive adenocarcinoma with ground-glass opacity (GGO) after VATS lobectomy.
Detailed Description
On HRCT screening, early lung adenocarcinoma often contains a nonsolid component called ground-glass opacity (GGO). In 2011, pulmonary adenocarcinomas were classified into atypical adenomatous hyperplasia (AAH), adenocarcinoma in situ (AIS), minimally invasive carcinoma (MIA) and more extensively invasive adenocarcinoma (IAC) [1]. Early adenocarcinomas with GGO-dominant always mean low-grade malignancy and have an extremely favorable prognosis [2-5]. Previous studies have shown that patients with AAH, AIS and MIA have excellent survival rates (5-year survival rate is approximate 95%) after resection, and only 0.83% - 2.91% patients have lymph node metastasis [6-9]. At present, lymphadenectomy is always undergone in patients with pulmonary adenocarcinoma with ground-glass opacity. However, for MIA patients (especially in T1a-b stage), the appropriate use of lymphadenectomy continues to be debated. Nowadays, intraoperative frozen pathology is widely used during operation. However, whether sampling of lymph nodes or lymphadenectomy should be performed for GGO lesions according to intraoperative pathological diagnosis is unclear. The aim of this prospective study is to evaluate whether there are any trends regarding the impact of subtypes of invasive adenocarcinoma according to intraoperative frozen pathology in sampling of lymph nodes vs. lymphadenectomy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lymph Node Excision

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
600 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Lymphadenectomy
Arm Type
Active Comparator
Arm Description
systematically Lymphadenectomy of the lymph-node stations ATS 2, 4, 7, 8, 9,10,11 on the right side and ATS 5, 6, 7, 8, 9,10,11 on the left side
Arm Title
systematic sampling of the lymph nodes
Arm Type
Experimental
Arm Description
systematic sampling of the lymph-node stations ATS 2, 4, 7, 8, 9,10,11 on the right side and ATS 5, 6, 7, 8, 9,10,11 on the left side
Intervention Type
Procedure
Intervention Name(s)
systematic sampling of the lymph-node
Intervention Description
Systematic Sampling of lymph nodes
Intervention Type
Procedure
Intervention Name(s)
lymphadenectomy
Intervention Description
Routine lymph nodes dissection in lung cancer
Primary Outcome Measure Information:
Title
recurrence-free survival
Description
recurrence-free survival status of patients after surgery
Time Frame
five years after surgery
Secondary Outcome Measure Information:
Title
Overall Survival
Description
survival status of patients after surgery
Time Frame
five years after surgery
Title
Morbidity rate
Description
the rates of complications related to treatment during perioperative period
Time Frame
up to 30 days after surgery
Title
Mortality rate
Description
the rates of death related to treatment during perioperative period
Time Frame
up to 30 days after surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: A peripheral nodular lesion; The maximum diameters of whole GGO lesions and solid components on lung windows were no more than 3 cm (T1 stage); VATS lobectomy 25%≦Consolidation/Tumor ratio ≦50% ECOG performance status 0-2; Without distant metastasis; Intraoperative frozen pathology confirmed invasive or minimally invasive adenocarcinoma. No operation contraindication Cardiovascular: Cardiac function normal Renal: Creatinine clearance greater than 60 ml/min The expected survival after surgery ≥ 6 months Must be able to sign written informed consent form Exclusion Criteria: Age less than 18 years old Known hereditary bleeding disorder with history of post-operative hemorrhage Patients maintained on chronic anticoagulation (eg Coumadin therapy) Known hematogenous disorder Known primary or secondary malignancy Pregnant or breast-feeding women; Clinically significant heart disease; Patients who are unwilling or unable to comply with study procedures; Receiving immunosuppressive therapy; HIV/AIDS. Multiple lesions in lung
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Chang Chen, M.D. Ph.D.
Phone
13816869003
Email
chenthoracic@163.com
Facility Information:
Facility Name
Shanghai Pulmonary Hospital
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chang Chen, MD,PhD
Phone
13816869003
Email
chenthoracic@163.com

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
24551879
Citation
Tsutani Y, Miyata Y, Nakayama H, Okumura S, Adachi S, Yoshimura M, Okada M. Appropriate sublobar resection choice for ground glass opacity-dominant clinical stage IA lung adenocarcinoma: wedge resection or segmentectomy. Chest. 2014 Jan;145(1):66-71. doi: 10.1378/chest.13-1094.
Results Reference
result
PubMed Identifier
24841547
Citation
Ye B, Cheng M, Li W, Ge XX, Geng JF, Feng J, Yang Y, Hu DZ. Predictive factors for lymph node metastasis in clinical stage IA lung adenocarcinoma. Ann Thorac Surg. 2014 Jul;98(1):217-23. doi: 10.1016/j.athoracsur.2014.03.005. Epub 2014 May 17.
Results Reference
result

Learn more about this trial

Systematic Sampling of Lymph Nodes vs. Lymphadenectomy According to Intraoperative Frozen Pathology for Pulmonary Invasive Adenocarcinoma With Ground-glass Opacity

We'll reach out to this number within 24 hrs